Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2016

01-04-2016 | Review Article

Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients

Authors: Ugo Testa, Francesco Lo-Coco

Published in: Annals of Hematology | Issue 5/2016

Login to get access

Abstract

All trans retinoic acid (ATRA) has revolutionized the therapy of acute promyelocytic leukemia (APL). Treatment of this leukemia with ATRA in combination with chemotherapy has resulted in complete remission rates >90 % and long-term remission rates above 80 %. Furthermore, the combination of ATRA and arsenic trioxide (ATO) was shown to be safe and effective in frontline treatment and, for patients with low and intermediate risk disease, possibly superior to the standard ATRA and anthracycline-based regimen. However, in spite of this tremendous progress, APL still remains associated with a high incidence of early death due to the frequent occurrence of an abrupt bleeding diathesis. This hemorrhagic syndrome more frequently develops in high-risk APL patients, currently defined as those exhibiting >10 × 109/L WBC at presentation. In addition to high WBC count, other molecular and immunophenotypic features have been associated with high-risk APL. Among them, the expression in APL blasts of the stem/progenitor cell antigen CD34, the neural adhesion molecule (CD56), and the T cell antigen CD2 help to identify a subset of patients at higher risk of relapse and often the expression of these markers is associated with high WBC count. At the molecular level, the short PML/RARA isoform and FLT3-internal tandem duplication (ITD) mutations have been associated with increased relapse risk. These observations indicate that extended immunophenotypic and molecular characterization of APL at diagnosis including evaluation of CD2, CD56, and CD34 antigens and of FLT3 mutations may help to better design risk-adapted treatment in this disease.
Literature
1.
Lo-Coco F, Hasan SK (2014) Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol 27:3–9CrossRefPubMed
2.
Ablain J, De Thé H (2014) Retinoic acid signaling in cancer: the parable of acute promyelocytic leukemia. Int J Cancer 135:2262–2272CrossRefPubMed
3.
Vickers M, Jackson G, Taylor P (2000) The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 17:722–726CrossRef
4.
Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al (2012) The origin and evolution of mutations in acute myeloid leukemia. Cell 150:264–278CrossRefPubMedPubMedCentral
5.
Cancer Gemome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059–2074CrossRef
6.
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–572PubMed
7.
Mi JQ, Chen SJ, Zhou GB, Yan XJ, Chen Z (2015) Synergistic targeted therapy for acute promyelocyticleukaemia: a model of translational research in human cancer. J Int Med; in press
8.
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121CrossRefPubMed
9.
Lo-Coco F, Cicconi L (2014) What is the standard regimen for patients with acute promyelocytic leukemia? Curr Hematol Malig Rep 9:138–143CrossRefPubMed
10.
Muroi K, Fujiwara S, Tatara R, Sugimoto M, Yamamoto C, Uehara E et al (2013) CD56 expression in normal immature granulocytes after allogeneic hematopoietic stem cell transplantation. J Clin Exp Hematol 53:247–250CrossRef
11.
Montesinos P, Rayon C, Vellenga E, Brunet S, Gonzalez T, Gonzalez M et al (2011) Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimes. Blood 117:1799–1805CrossRefPubMed
12.
Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T et al (2014) Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. Cancer Sci 105:97–104CrossRefPubMedPubMedCentral
13.
Breccia M, De Propris MS, Minotti C, Stefanizzi C, Raponi S, Colofigli G et al (2014) Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. Leuk Res 38:194–197CrossRefPubMed
14.
Lou Y, Ma Y, Suo S, Ni W, Wang Y, Pan H et al (2015) Prognostic significance of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline. Leuk Res 39:938–944CrossRefPubMed
15.
De J, Zanjani R, Hibbard M, Dabis BH (2007) Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia. Am J Pathol 128:550–557
16.
Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nasrdi G et al (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15:1161–1164CrossRefPubMed
17.
Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, Chen B et al (2009) AML1-ETO9 is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia. Leukemia 23:1598–1604CrossRefPubMed
18.
Nishii K, Usui E, Katayama N, Lorenzo F, Nakase K, Kobayashi T et al (2003) Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia 17:731–737CrossRefPubMed
19.
Lin P, Hao S, Medeiros LJ, Estey EH, Pierce SA, Wang X et al (2004) Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. Am J Clin Pathol 121:402–407CrossRefPubMed
20.
Biondi A, Luciano A, Bassan R, Mininni D, Specchia G, Lanzi E et al (1995) CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia 9:1461–1466PubMed
21.
Albano F, Mestice A, Pannunzio A, Lanza F, Martino B, Pastore D et al (2006) The biological characteristics of CD34+CD2+ adult acute promyelocytic leukemia and the CD34−CD2− hyergranular and microgranular (M3v) phenotypes. Haematologica 91:311–316PubMed
22.
Xu F, Yin CX, Wang CL, Jiang XJ, Jiang L, Wang ZX et al (2014) Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis. Dis Mark. art id 421906
23.
Foley R, Soamboonsrup P, Carter RF, Benger A, Meyer R, Walker I et al (2001) CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol 67:34–41CrossRefPubMed
24.
Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnoldi A et al (1998) Immunophenotype of adult and childhood acute promyelocytic leukemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 102:1035–1041CrossRefPubMed
25.
Lee JJ, Cho D, Chung IJ, Cho SH, Park KS, Park MR et al (2003) CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia. Am J Haematol 73:149–153CrossRef
26.
Paietta E, Golonbeva O, Neuberg D, Bennett JM, Gallagher R, Racevskis et al (2004) A surrogate marker profile of PML/RARalpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry Part B 59B:1–9CrossRef
27.
Breccia M, De Propris MS, Stefanizzi C, Raponi S, Modica M, Colafigli G et al (2014) Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. Ann Hematol 93:1819–1823CrossRefPubMed
28.
Chendamarai E, Ganesan S, Alex AA, Kamath V, Nair SC, Nellickai AJ et al (2015) Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PLoS ONE 10, e0121912CrossRefPubMedPubMedCentral
29.
Tallman M, Lo-Coco F, Kwaan H, Sanz M, Gore S (2011) Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia. Clin Adv Hematol Oncol 9:1–16
30.
Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL et al (2011) Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 118:1248–1254CrossRefPubMedPubMedCentral
31.
Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 93:4131–4143PubMed
32.
Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al (2000) Definition of relapse risk and the role of non-anthracycline drugs for consolidation in patients with acute promyeloctic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed
33.
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Eur APL Group Blood 94:1192–1200
34.
Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J et al (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gentuzumabozogamicin. J Clin Oncol 27:504–510CrossRefPubMed
35.
Mathews V, George B, Lakhmi KM, Viwabandya A, Bajel A, Balasubramanian P et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627–2632CrossRefPubMed
36.
Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovek S, Jones D et al (2006) Use of all-trans retinoic acid plus arsenic trioxide ad an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469–3473CrossRefPubMed
37.
Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C et al (2015) Clinical characteristics and outcomes in patients with acute promyelocytic leukemia and hyperleukocytosis. Br J Haematol 168:646–653CrossRefPubMedPubMedCentral
38.
Montesinos P, Beagua J, Vellenga E, Rayen C, Parody R, de la Serna J et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775–783CrossRefPubMed
39.
Kiyoi H, Naoe T, Yokota N, Nakao M, Minami S, Kuriyama K et al (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (KOHseisho). Leukemia 11:1447–1452CrossRefPubMed
40.
Moreno I, Martin G, Bolufer P, Barragan E, Rueda E, Roman J et al (2003) Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 88:19–24PubMed
41.
Kelly LM, Kutok JL, Williams IR, Boulton CL, Curley DP, Amaral SM et al (2002) PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A 99:8283–8288CrossRefPubMedPubMedCentral
42.
Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM et al (2003) A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101:3188–3197CrossRefPubMed
43.
Breccia M, Avvisati G, Latagliata R, Carmosino I, Guarini A, De Propris MS et al (2007) Occurrence of thrombotic events in acute promyelocytic leukemia correlate with consistent immunophenotypic and molecular features. Leukemia 21:79–83CrossRefPubMed
44.
Mitrovic M, Suvajdzic N, Elezovic I, Bogdanovic A, Djordjevic V, Miljic P et al (2015) Thrombotic events in acute promyelocytic leukemia. Thromb Res 135:588–593CrossRefPubMed
45.
Gale RE, Hills R, Pizzey A, Kottaridis PD, Swirsky D, Gilkes AF et al (2005) Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106:3768–3778CrossRefPubMed
46.
Souza Melo CP, Campos CB, Dutra AP, Neto JCA, Fenelon AJS, Neto AH et al (2015) Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias. Leuk Res 39:131–137CrossRefPubMed
47.
Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J et al (2012) FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from Children’s Oncology Group. Pediatr Blood Cancer 59:662–667CrossRefPubMedPubMedCentral
48.
Takenokuchi M, Kawano S, Nakamachi Y, Sakota Y, Syampurnawayi M, Saigo K et al (2012) FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia. Haematol Rep 4, e22
49.
Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S et al (2002) Alterations of the FLT3 gene in acute promyelocyticleukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 16:2185–2189CrossRefPubMed
50.
Molica M, Breccia M (2015) FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. Leuk Res 39:397–399CrossRefPubMed
51.
Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R et al (2014) Internal tandem duplication of the FLT3 gene confer poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on acute promyelocytic leukemia study. Ann Hematol 93:2011–2010CrossRef
52.
Chillon MC, Santamaria C, Garcia-Sanz R, Balanzategui A, Saraquete ME, Alcocebeda M et al (2010) Log FLT3 internal tandem duplications and reduced PML-RARalpha expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Hematologica 95:745–752CrossRef
53.
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M et al (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120:1570–1580CrossRefPubMed
54.
Shen Y, Fu YK, Zhu YM, Lou YJ, Gu ZH, Shi JY et al (2015) Mutations of epigenetic modifier genes as a poor prognostic factor in acute promyelocytic leukemia under treatment with all-trans retinoic acid and arsenic trioxide. Electromagn Biol Med 2:563–571
55.
Gaur GC, Ramadan S, Cicconi L, Noguera NI, Luna I, Such E et al (2012) Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocyticleukemia. Ann Hematol 91:1855–1860CrossRefPubMed
56.
Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M et al (2015) WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia 29:660–667CrossRefPubMed
57.
Cervera J, Montesinos P, Hernandez-Rivas J, Calosanz MJ, Aventin A, Ferro MT et al (2010) Additional chromosomal abnormalities treated with all-trans retinoic acid and chemotherapy. Haematologica 95:424–431CrossRefPubMedPubMedCentral
58.
De Botton S, Chevret S, Canz M, Dombret H, Thomas X, Guerci A et al (2010) Additional chromosomal abnormalities in patients with acute promyelocytic leukemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 111:801–806
59.
Albano F, Zagaria A, Anelli L, Orsini P, Minervini CP, Impera L et al (2013) Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia. Oncotarget 5:649–658CrossRefPubMedCentral
60.
Hecht A, Nowak D, Nowak V, Hanfstein B, Faldum A, Buchner T et al (2013) High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival. Ann Hematol 92:443–449CrossRefPubMed
61.
Lucena-Araujo AR, Kim H, Jacomo RH, Melo RA, Bittencourt R, Pasquini R et al (2014) Prognostic impact of KMT2E transcript level on outcome of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium of Acute Promyelocytic Leukemia study. Br J Haematol 166:540–549CrossRefPubMed
62.
Lucena-Araujo AR, Kim H, Thomé C, Jacomo RH, Melo RA, Bittencourt R et al (2015) High ΔNp73/Tap73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood 126:2302–2306CrossRefPubMedPubMedCentral
63.
Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrilow LJ et al (2012) A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 119:196–205CrossRefPubMed
64.
Breccia M, Lo-Coco F (2014) Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. Thromb Res 133(S2):S112–S116CrossRefPubMed
65.
Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard S et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 25:1128–1134CrossRefPubMed
66.
McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA et al (2012) Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 97:133–136CrossRefPubMedPubMedCentral
67.
Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL et al (2013) Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 37:1004–1009CrossRefPubMed
68.
Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A et al (2014) Acute promyelocytic leukemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukemia referral centres: a pan-Canadian epidemiological study. Br J Haematol 166:660–666CrossRefPubMed
69.
de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402CrossRefPubMed
70.
Burnett A, Hunter A, Khwaja A, Bowen D, Grimwade D, Hills R et al (2015) APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA. EHA Meeting, abstract LB 2067
Metadata
Title
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients
Authors
Ugo Testa
Francesco Lo-Coco
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2622-1

Other articles of this Issue 5/2016

Annals of Hematology 5/2016 Go to the issue

Original Article

Leukemogenic potency of the novel FLT3-N676K mutant

Original Article

Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults

Original Article

Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years

Original Article

Serum zinc levels in patients with iron deficiency anemia and its association with symptoms of iron deficiency anemia

Original Article

Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

Erratum

Erratum to: Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years’ follow-up in Egypt
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits